Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced the appointment of Brent Saunders as chief executive officer (“CEO”) and chair of the Board of Directors (“Board”) of the Company, effective March 6, 2023. Concurrent with this appointment, and as previously announced, Joseph C. Papa will step down from his roles as CEO and director.

Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023

Salix to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC / ACCESSWIRE / February 13, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) today announced the opening of the 2023 Salix Gastrointestinal Health Scholars Program application period. The program will award 10 exceptional students living with GI disease a scholarship of up to $10,000 as they work to pursue their higher education goals.

Salix Announces 2023 Gastrointestinal Health Scholars Program

Crown Hlds

CVR Energy

FirstEnergy

Herc Hlds

Icahn Enterprises

Newell Brands

Southwest Gas Hlds

Xerox

Carl Icahn is one of the most successful investors of all time and is the founder and controlling shareholder of Icahn Enterprises.

These Are the Top 10 Holdings of Carl Icahn

LAVAL, QC / ACCESSWIRE / February 1, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its fourth-quarter and full-year financial results on Thursday, Feb. 23, 2022. Bausch Health will host a conference call and live webcast at 8:00 a.m.

Bausch Health to Announce Fourth-Quarter and Full-Year 2022 Results on Feb. 23

Bausch + Lomb Corp

VAUGHAN, Ontario & TAMPERE, Finland--( BUSINESS WIRE )--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and Modulight Corporation (“Modulight”), a biomedical laser company, today announced that the U.S. Food and Drug Administration (FDA) has approved the ML6710i photodynamic laser for equivalent use with Bausch + Lomb's VISUDYNE® (verteporfin for injection) photodynamic therapy (PDT) for the treatment of patients with predominantly classic subfoveal choroidal neovascularization, or the creation of abnormal choroidal blood vessels, due to Age-related Macular Degeneration (AMD).1 ML6710i is expected to be available for eye care professionals during the first half of 2023.

Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb's VISUDYNE® (Verteporfin for Injection)

VAUGHAN, Ontario--( BUSINESS WIRE )--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2022 financial results on Wednesday, Feb. 22, 2023. Bausch + Lomb will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22

VAUGHAN, Ontario--( BUSINESS WIRE )--Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced that Joseph C. Papa, chief executive officer, and Sam Eldessouky, executive vice president and chief financial officer, are scheduled to participate at the 41st Annual J.P. Morgan Healthcare Conference on Jan. 9, 2023, at 3:00 p.m. PT (6:00 p.m. ET).

Bausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference

Agnico Eagle Mines

APA Corporation

Anglogold Ashanti Plc

BrightSphere Investment Group

Horizon Pharma

Perpetua Resources Corp

SSR Mining

John Paulson is the founder, president and portfolio manager at Paulson & Co.

These Are The Top 10 Holdings Of John Paulson

Shares of Bausch Health are down over 70% this year. Underwhelming earnings and developments around the Xifaxan patent have been the primary drivers of underperformance vs. the broader equity market.

Bausch Health: Things To Consider Before Investing

ACCO Brands

Anywhere Real Estate Inc

ACCO, BHC and HOUS have been added to the Zacks Rank #5 (Strong Sell) List on December 9, 2022.

New Strong Sell Stocks for December 9th

LAVAL, QB / ACCESSWIRE / December 2, 2022 / Bausch Health Companies Inc. (NYSE/TSX:BHC) today announced that the US District Court for the District of New Jersey issued a favorable decision regarding DUOBRII® and BRYHALI®, in a suit filed against Padagis Israel Pharmaceuticals LTD and Padagis US LLC. According to the ruling, the District Court found all the asserted patents valid and infringed.

Bausch Health Wins DUOBRII(R) and BRYHALI(R) Patent Infringement Case

Launching in December for Constipation Awareness Month, Initiatives Include Partnerships with Well-Known Lifestyle and Health Care Practitioner Influencers Campaign Coincides with Salix's Continued Support of Advocacy Groups Building Innovative Patient Education Programs and Advancing Disease State Research in 2023 LAVAL, QC / ACCESSWIRE / December 1, 2022 / Salix Pharmaceuticals ("Salix"), the gastroenterology business of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health"), today announced the launch of a series of social media and digital initiatives to raise awareness during Constipation Awareness Month in December. The initiatives will discuss constipation diseases, including opioid-induced constipation (OIC), irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

Salix Pharmaceuticals Culminates Year-Long Constipation Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care Provider

LAVAL, QC / ACCESSWIRE / November 29, 2022 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") has designated 1261229 B.C. Ltd., the entity that directly or indirectly holds 88.7% of the issued and outstanding shares of Bausch + Lomb Corporation ("Bausch + Lomb"), as an unrestricted subsidiary of the Company in accordance with the terms of the Company's debt documents.

Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Documents

Bausch (BHC) Q3 earnings and sales decline year over year due to the unfavorable impact of foreign exchange rates. The company also lowers its annual guidance.

Bausch (BHC) Q3 Earnings & Sales Miss, Guidance Lowered

LAVAL, QC / ACCESSWIRE / November 4, 2022 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals ("Salix"), today announced one de novo abstract that is being presented at The Liver Meeting® 2022, organized by the American Association for the Study of Liver Diseases (AASLD), which is taking place November 4-8 in Washington, D.C. The abstract being presented at AASLD's The Liver Meeting 2022 is: Sanyal, A.

Salix Will Present Rifaximin Data at AASLD's The Liver Meeting(R) 2022

Bausch Health Companies Inc. (NYSE:BHC ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Christina Cheng - Senior Vice President, Investor Relations and Communications Thomas Appio - Chief Executive Officer Tom Vadaketh - Chief Financial Officer Conference Call Participants Gary Nachman - BMO Capital Markets Georgi Yordanov - Cowen Umer Raffat - Evercore Greg Fraser - Truist Securities Douglas Miehm - RBC Capital Markets Rishi Parekh - JPMorgan Operator Good morning, ladies and gentlemen and welcome to the Bausch Health Third Quarter 2022 Earnings Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Christina Cheng, Senior Vice President, Investor Relations and Communications at Bausch Health.

Bausch Health Companies Inc. (BHC) Q3 2022 Earnings Call Transcript

Bausch (BHC) delivered earnings and revenue surprises of -17.39% and 2.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Misses Q3 Earnings and Revenue Estimates

Revenues of $2.046 billion, down 3% reported, up 2% organic basis Third quarter sales improved sequentially, notably Salix, International, and Solta Successful debt exchange offer reduces debt by $2.5 billion Company updates full year guidance LAVAL, QC / ACCESSWIRE / November 3, 2022 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third-quarter 2022 financial results. "We are encouraged with the top line improvement in the third quarter, with four out of five segments delivering growth on an organic basis 1 ," Thomas J.

Bausch Health Announces Third-Quarter 2022 Results

Nine Poster Presentations Include New Analyses of SILIQ ® and JUBLIA® LAVAL, QC / ACCESSWIRE / November 1, 2022 / - Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, today announced the presentation of nine posters during the Innovations in Dermatology Conference, which takes place Nov. 3-5, 2022, in Las Vegas, Nev. The presentations will feature new data around JUBLIA® (efinaconazole) Topical Solution, 10%, and SILIQ® (brodalumab) Injection, 210 mg/1.5 mL.

Ortho Dermatologics to Present New Data at the 2022 Innovations in Dermatology Conference

New Educational Resource Designed to Help Support the Podiatry Community Company Also Adds 300 Questions to Existing Dermatology Board Review Challenge LAVAL, QC / ACCESSWIRE / October 31, 2022 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, recently announced the launch of the Podiatry Board Review Challenge, a new professional educational resource. Developed alongside practicing podiatrists, the Podiatry Board Review Challenge is designed to help support residents preparing for their board certification exams, podiatric healthcare professionals preparing for re-certifications and podiatrists who are looking to refresh their skills and knowledge.

Ortho Dermatologics Announces U.S. Launch of the Podiatry Board Review Challenge

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Bausch Health (BHC) Q3 Earnings Expected to Decline

LAVAL, QC / ACCESSWIRE / October 24, 2022 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals ("Salix"), today announced four posters and one abstract featuring data for XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and RELISTOR® (methylnaltrexone bromide) that are being presented at the American College of Gastroenterology® (ACG) 2022 Annual Scientific Meeting, which is taking place October 21-26 in Charlotte, North Carolina. The complete list of Salix research being featured at ACG 2022 includes: XIFAXAN Staller, Kyle et al.

Salix Will Present XIFAXAN(R) (Rifaximin), TRULANCE(R) (Plecanatide) and RELISTOR(R) (Methylnaltrexone Bromide) Data at The American College of Gastroenterology(R) 2022 Annual Scientific Meeting

Eleven Poster Presentations Include New Analyses of ARAZLO®, DUOBRII®, and IDP-126 Gel LAVAL, QC / ACCESSWIRE / October 20, 2022 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, today announced the presentation of eleven posters during the Fall Clinical Dermatology Conference, which takes place Oct. 20-23, 2022 in Las Vegas, Nev. The presentations will feature new data around ARAZLO® (tazarotene) Lotion, 0.045%, DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, and the investigational medicine IDP-126 Gel-a combination retinoid, antibacterial and antibiotic topical.

Ortho Dermatologics To Present New Data at the 2022 Fall Clinical Dermatology Conference

LAVAL, QC / ACCESSWIRE / October 13, 2022 / Bausch Health Companies Inc. (NYSE/TSX:BHC) ("Bausch Health") will release its third quarter financial results on Thursday, Nov. 3, 2022. Bausch Health will host a conference call and live webcast at 8:00 a.m.

Bausch Health to Announce Third Quarter 2022 Results on Nov. 3

Released During Liver Health Awareness Month and Based Primarily on HCP-Market Research, Salix Pharmaceuticals' Liver Health Annual Trends Report Finds More than One-Third of Gastroenterologists Surveyed Have Seen an Increase in Patient Hospitalizations Due to Cirrhosis Over the Past Year Report Points to Reimbursement Challenges as Negatively Affecting Management of Chronic Liver Disease, as Reported by Survey Respondents LAVAL, QC , Oct. 12, 2022 /PRNewswire/ -- Salix Pharmaceuticals ("Salix"), the gastroenterology business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today released the Salix Liver Health Annual Trends Report, Second Edition with the latest information on chronic liver disease (CLD) care and findings that include a continued rise in hospitalizations and mortality from CLD and cirrhosis, as well as gaps in care and knowledge that may prevent early diagnosis and optimal management of CLD, cirrhosis and its complications. The trends report, which is based on a survey of 400 health care providers (HCPs) who treat patients with CLD, qualitative interviews with HCPs, and secondary research from peer-reviewed publications, reveals shortfalls in the adoption of national treatment guidelines, particularly among primary care physicians (PCPs).

SALIX PHARMACEUTICALS RELEASES LIVER HEALTH ANNUAL TRENDS REPORT UNDERSCORING CHALLENGES IN CARING FOR GROWING CHRONIC LIVER DISEASE AND CIRRHOTIC PATIENT POPULATION

News for Bausch Health Companies Inc Stock (BHC)